Company intelligence / Profile preview

3PG

Pamplona area, Navarra, Spain3pgc.org ↗

Ownership: Private
Employees: ~240
Development stage: Other

Overview

Formed by the merger of two leading European CDMOs—Spain’s 3P Biopharmaceuticals and Finland’s BIOVIAN—now operating as a global provider of end-to-end biologics development and manufacturing solutions. The company offers process development through commercial-scale cGMP production for advanced biologics including recombinant proteins, viral vectors for gene therapy, cell therapies, and plasmid DNA. No proprietary clinical programs; operates as a service provider to biotech/pharma clients[1].

Modalities: Recombinant proteinViral vectorPlasmid DNACell therapy
Industry: Contract Manufacturing Organization

Partnerships

Multiple partnerships with biotech/pharma companies globally as clients.Merger between two major European CDMOs ("BIOVIAN" and "3P Biopharmaceuticals")

Beyond the preview

Go deeper on 3PG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3PG.

Explore the full profile